July 31, 2026

To, **National Stock Exchange of India Limited**, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, **BSE Limited**, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	**Scrip Code: 532296**
ISIN: INE935A01035	**ISIN: INE935A01035**
Our Reference No. 38/26-27	**Our Reference No. 38/26-27**

Dear Sir/ Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation – Q1 FY 26-27.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Rashmi Khandelwal
Digitally signed by Rashmi Khandelwal
Date: 2026.07.31 19:15:41 +05'30'

Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839

Encl: As above

Investor Presentation
Q1 FY27

31 July 2026

glenmark
A new way for a new world

Disclaimer

This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company's or its affiliates' objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects", "aspirations", "goals", "aim", "targets", "promises" and similar expressions.

These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation:

- General economic and political conditions in our key markets, government policies and other incidental factors;
- Changes in the overall macro-economic parameters including changes in the currency and interest rates either in India and / or globally;
- Ability to successfully implement our strategic plan, including research and development efforts;
- Changes in laws and regulations that apply to the pharmaceutical industry and its suppliers and customers; and
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry

Actual outcomes may vary materially from those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Certain information in this document is not audited or reviewed by an auditor or based on Indian Accounting Standards or internationally accepted accounting principles. The reader should not consider such items as an alternative to the audited financial results or other indicators of the Company's profit, cash flows or financial performance based on applicable accounting standards.

Summary – Q1 FY27

Consolidated Revenue

- Consolidated Revenue of Rs. 40,185 million
- YoY growth of 23.1%

Regional Highlights

- India business growth of 15.5%
- North America core business growth of 19.8%
- EU business growth of 11.9%
- EM business growth of 27.7%

Profitability

- Consolidated R&D at Rs. 2,494 million
- EBITDA at Rs. 8,048 million
- EBITDA margin of 20.03%
- PAT at Rs. 4,828 million with PAT margin of 11.8%

"We have started FY27 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-to-market respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business. The results reinforce the direction of Glenmark's next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI's pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value."

Glenn Saldanha
Chairman and Managing Director
Glenmark Pharmaceuticals Ltd.

Consolidated Revenue – Q1 FY27

	First Quarter ended June 30		
Rs. million	**FY 2027**	**FY 2026**	**YoY Growth**
India	*14,321*	*12,399*	*15.5%*
North America [#]	*10,974*	*7,780*	*41.1%*
Europe	*7,472*	*6,678*	*11.9%*
Emerging Markets [##]	*7,304*	*5,721*	*27.7%*
Total	**40,071**	**32,578**	**23.0%**
Other Revenue	*114*	*66*	*72.4%*
Consolidated Revenue	**40,185**	**32,644**	**23.1%**

Average conversion rate in 3M FY 2026-27 considered as INR 94.53 / USD 1.00

Average conversion rate in 3M FY 2025-26 considered as INR 85.54 / USD 1.00

USD figures are only indicative

[#] *North America revenue for Q1 FY27 includes deferred out-licensing income recognition for ISB 2001*

[##] *Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC)*

India

- Significant outperformance compared to IPM in terms of secondary sales
- Continues to be top-ranked in its core therapeutic areas
- New launches in Respiratory & Oncology continue to gain scale
- Continued strong growth in Glenmark Consumer Care franchise

Revenue (Rs. million)



North America

- Launched 9 new products in Q1 FY27
- First generic approval of FloVent® HFA 44 mcg with 180-day CGT exclusivity
- Fluticasone Nasal Spray [OTC] launched, three additional Respiratory ANDAs filed earlier
- Initiated commercialization of RYALTRIS® in the USA
- Re-launched Fulvestrant Injection from Monroe in Q1 FY27

Revenue (Rs. million)#



 # North America revenue for Q1 FY27 includes deferred out-licensing income recognition for ISB 2001

Europe

- Continued strong growth in branded markets / products
- Increasing contribution from Branded portfolio across Respiratory and Dermatology
- RYALTRIS® continues to gain market share across the region; additional 8 products launched
- Expansion of the branded Dermatology portfolio - WINLEVI® launched in UK + select EU markets, HILKOTA™ approved in Nordic countries

Revenue (Rs. million)



Emerging Markets

- Continued outperformance in Russia Dermatology market
- Very strong secondary sales growth in LATAM and MEA markets
- Respiratory portfolio continues out-performance in the covered market
- RYALTRIS® continues to be the leading nasal spray in the region
- RYALTRIS® launched in China and Thailand in Q4 FY26; targeting Brazil launch in H2 FY27

Revenue (Rs. million)



Global Innovative Portfolio Update

RYALTRIS®

- Commercialized in 57 markets
- Launched in China, Thailand in Q4 FY26
- Initiated commercialization in the USA
- Robust secondary sales growth of >40 in Q1 FY27

WINLEVI®

- Launched in several EU markets – Nordics, CEE and Spain
- Continued uptake in the UK since launch in FY26

QiNHAYO™ (ENVAFOLIMAB)

- Marketing authorization applications filed in 24 countries
- Initiated early access programs or Named Patient Programs in seven markets
- Initiated a global multi-center Phase 3 study in neo-adjuvant and adjuvant NSCLC

TRASTUZUMAB REZETECAN

- First wave of MA applications to begin Q2 FY27
- Glenmark initiated Phase 3 clinical trial in Platinum-resistant Ovarian Cancer (PROC) in India

AUMOLERTINIB

- Submitted MA applications in 13 markets as of June 2026
- First commercial launch anticipated during H2 FY27

Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases

ONCOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS
ISB 2001 (ABBV-2001)	CD38 x BCMA x CD3 Trispecific T-cell engager	Multiple Myeloma						abbvie / Glenmark
ISB 2301	Multispecific immune cell activator	Solid Tumors						IGI
ISB 2302	Bispecific immune modulator	Hematologic & Solid Tumors						IGI
ISB 2501	Trispecific T-cell engager	Solid Tumors						IGI

*IGI will partner with Glenmark to develop, manufacture, and commercialize ISB 2001 in all territories outside AbbVie's licensed markets

IMMUNOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS
ISB 880 (LAD191)	IL-1RAP antagonist mAb	Hidradenitis Suppurativa						almirall
Telazorlimab (ISB 830) ISB 830-X8 (STAR-0310)	OX40 antagonist mAb	Atopic Dermatitis						bio cryst

Oncology Immunology

IGI - Key updates

- **ISB 2001/ABBV-2001**
  - To date, >160 subjects have been dosed in the TRIgnite 1 Phase 1 study (42 in dose escalation and >120 in dose expansion)
  - Safety and efficacy data from all subjects continue to be promising and are consistent with the data previously presented at ASCO 2025
  - A Phase 1/2 multi cohort combination study in Multiple Myeloma with other antimyeloma therapies has been initiated (NCT06892522)
- **ISB 2301**
  - A first-in-class multispecific™ immune cell activator targeting solid tumors; IGI intends to submit and IND later this year (CY26).
- **ISB 2302** (Bispecific immune modulator) and **ISB 2501** (Trispecific T-cell engager), are both in early preclinical development.



glenmark
A new way for a new world